A Phase 1 interventional study of IMC-1121B in Advanced Solid Tumors, sponsored by Eli Lilly and Company. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-06-18.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This trial is testing the investigational drug IMC-1121B administered to Japanese participants with advanced solid tumors who have not responded to standard therapy or for whom no standard therapy is available. The rationale for performing this trial is to establish the safety profile and the pharmacokinetics of IMC-1121B.
This single center, open-label, single-arm, Phase 1 study will enroll approximately 15 to 18 participants. The actual size will vary depending on the dose-limiting toxicities (DLTs) observed and the resultant sizes of the cohorts. Participants will receive IMC-1121B, administered intravenously, once every 2 or 3 weeks for 6 weeks (one cycle). After one cycle of treatment, participants who have an objective response or stable disease may continue to receive IMC-1121B at the same dose and schedule until disease progression or other withdrawal criteria are met. A minimum of three participants will be enrolled in each cohort. Dose escalation in successive cohorts will occur once all participants complete one cycle of therapy.
Participants will be enrolled sequentially into each cohort.
A completed participant will be either a participant who completes the initial 6 week treatment period (Cycle 1) or a participant who discontinues therapy for an IMC-1121B related toxicity during Cycle 1. Participants who do not complete the first 6 weeks of treatment for reasons other than an IMC-1121B -related toxicity will be replaced. Toxicity data for each cohort will be reviewed prior to dose escalation. Upon completion of all required safety evaluations during the initial 6 weeks, the next cohort of new participants will be treated at the next higher dose level using a dose escalation scheme.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receiving IMC-1121B intravenously
Biological: IMC-1121B
Cycle 1: Upon completion of enrollment criteria confirmed at screening, the first dose of study medication should be administered within 7 days. The infusion will be planned every 2 weeks or every 3 weeks on the same day of the week of the first infusion. Dose escalation to Cohort 2 may occur in the absence of a dose-limiting toxicity (DLT) in the first three participants treated in Cohort 1 during the initial 6-week dosing period (Cycle 1). The same procedure will be followed for dose escalation from Cohort 2 to Cohort 3. If 1 of 3 participants in any cohort experiences a DLT in the first 6 weeks (Cycle 1), 3 additional participants will be enrolled in that cohort. Dose escalation to the next cohort may occur if less that 2 of 6 participants experience a DLT during Cycle 1.
Also known as: RAMUCIRUMAB, LY3009806
Number of Participants With Drug-Related Adverse Events
Data presented are the number of participants who experienced adverse events (AE) of any grade, AE of Grade ≥3 based on National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 (NCI-CTCAE v 3.0), serious adverse events (SAE) and AE resulting in death that was considered to be related to IMC-1121B (ramucirumab). A summary of SAEs and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Event module.
Time frame: Baseline to study completion up to 48 weeks
IMC-1121B Pharmacokinetics: Maximum Serum Concentration (Cmax) - Cohorts 1 and 2 During Cycles 1 and 2
Time frame: Day 1 to Day 15 of Cycles 1 and 2 of a 6-week cycle
IMC-1121B Pharmacokinetics: Maximum Serum Concentration (Cmax) - Cohorts 1 and 2 During Cycles 3 to 5
Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, Cmax could not be calculated.
Time frame: Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose
IMC-1121B Pharmacokinetics: Area Under the Concentration (AUC) Versus Time Curve - Cohorts 1 and 2 During Cycles 1 and 2
AUC for Cycle 1 is AUC from time zero to infinity \[AUC(0-∞)\] and for Cycle 2 is AUC over a dosing interval (AUCτ).
Time frame: Day 1 to Day 15 of Cycles 1 and 2 of a 6-week cycle
IMC-1121B Pharmacokinetics: Area Under the Concentration (AUC) - Cohorts 1 and 2 During Cycles 3 to 5
Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, AUC could not be calculated.
Time frame: Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose
IMC-1121B Pharmacokinetics: Half-Life (t1/2) - Cohorts 1 and 2 During Cycles 1 and 2
Time frame: Day 1 to Day 15 of Cycles 1 and 2 of a 6-week cycle
IMC-1121B Pharmacokinetics: Half-Life (t 1/2) - Cohorts 1 and 2 During Cycles 3 to 5
Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, t1/2 could not be calculated.
Time frame: Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose
IMC-1121B Pharmacokinetics: Steady State Volume of Distribution (Vss) - Cohorts 1 and 2 During Cycles 1 and 2
Time frame: Day 1 to Day 15 of Cycles 1 and 2 of a 6-week cycle
IMC-1121B Pharmacokinetics: Steady State Volume of Distribution (Vss) - Cohorts 1 and 2 During Cycles 3 to 5
Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, Vss could not be calculated.
Time frame: Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose
IMC-1121B Pharmacokinetics: Maximum Serum Concentration (Cmax) - Cohort 3 During Cycles 1 and 2
Time frame: Day 1 to Day 22 of Cycles 1 and 2 of a 6-week cycle
IMC-1121B Pharmacokinetics: Maximum Serum Concentration (Cmax) - Cohort 3 During Cycles 3 to 5
Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, Cmax could not be calculated.
Time frame: Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose
IMC-1121B Pharmacokinetics: Area Under the Concentration (AUC) - Cohort 3 During Cycles 1 and 2
AUC for Cycle 1 is AUC from time zero to infinity \[AUC(0-∞)\] and for Cycle 2 is AUC over a dosing interval (AUCτ).
Time frame: Day 1 to Day 22 of Cycles 1 and 2 of a 6-week cycle
IMC-1121B Pharmacokinetics - Area Under the Concentration (AUC) - Cohort 3 During Cycles 3 to 5
Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, AUC could not be calculated.
Time frame: Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose
IMC-1121B Pharmacokinetics: Half-Life (t1/2) - Cohort 3 During Cycles 1 and 2
Time frame: Day 1 to Day 22 of Cycles 1 and 2 of a 6-week cycle
IMC-1121B Pharmacokinetics: Half-Life (t 1/2) - Cohort 3 During Cycles 3 to 5
Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, t1/2 could not be calculated.
Time frame: Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour postdose
IMC-1121B Pharmacokinetics: Steady State Volume of Distribution (Vss) - Cohort 3 During Cycles 1 and 2
Time frame: Day 1 and Day 22 of Cycles 1 and 2 of a 6-week cycle
IMC-1121B Pharmacokinetics: Steady State Volume of Distribution (Vss) - Cohort 3 During Cycles 3 to 5
Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, Vss could not be calculated.
Time frame: Cycles 3, 4 and 5 of a 6-week cycle: predose and 1 hour post-dose
Screen for the Development of Circulating Antibodies Against IMC-1121B (Immunogenicity)
Data presented are the number of participants with treatment emergent antibody positive.
Time frame: Baseline to study completion up to 48 weeks
| Milestone | IMC-1121B 6 mg/kg (Cohort 1) | IMC-1121B 8 mg/kg (Cohort 2) | IMC-1121B 10 mg/kg (Cohort 3) |
|---|---|---|---|
| Started | 3 | 6 | 6 |
| Received at least 1 dose of study drug | 3 | 6 | 6 |
| Completed | 3 | 6 | 6 |
| Not completed | 0 | 0 | 0 |
Data presented are the number of participants who experienced adverse events (AE) of any grade, AE of Grade ≥3 based on National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 (NCI-CTCAE v 3.0), serious adverse events (SAE) and AE resulting in death that was considered to be related to IMC-1121B (ramucirumab). A summary of SAEs and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Event module.
| participants | IMC-1121B 6 mg/kg (Cohort 1) | IMC-1121B 8 mg/kg (Cohort 2) | IMC-1121B 10 mg/kg (Cohort 3) |
|---|---|---|---|
| AE of any grade | 3 | 6 | 6 |
| AE of Grade ≥3 | 0 | 0 | 1 |
| SAE | 0 | 0 | 1 |
| AE resulting in death | 0 | 0 | 0 |
| micrograms/milliliter (mcg/mL) | IMC-1121B 6 mg/kg (Cohort 1) | IMC-1121B 8 mg/kg (Cohort 2) |
|---|---|---|
| Cycle 1 | 284 ± 63.7 | 371 ± 113 |
| Cycle 2 (n=1, 2) | 352 ± NA | 694 ± 123 |
Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, Cmax could not be calculated.
No measurements were reported for this outcome.
AUC for Cycle 1 is AUC from time zero to infinity \[AUC(0-∞)\] and for Cycle 2 is AUC over a dosing interval (AUCτ).
| micrograms*hour/milliliter (mcg*h/mL) | IMC-1121B 6 mg/kg (Cohort 1) | IMC-1121B 8 mg/kg (Cohort 2) |
|---|---|---|
| Cycle 1 - AUC(0-∞) (n=1, 1) | 36900 ± NA | 73800 ± NA |
| Cycle 2 - AUCτ (n=1, 2) | 56400 ± NA | 102000 ± 10400 |
Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, AUC could not be calculated.
No measurements were reported for this outcome.
| hours | IMC-1121B 6 mg/kg (Cohort 1) | IMC-1121B 8 mg/kg (Cohort 2) |
|---|---|---|
| Cycle 1 | 158 ± NA | 165 ± NA |
| Cycle 2 (n=0, 0) | NA ± NA | NA ± NA |
Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, t1/2 could not be calculated.
No measurements were reported for this outcome.
| milliliters/kilogram (mL/kg) | IMC-1121B 6 mg/kg (Cohort 1) | IMC-1121B 8 mg/kg (Cohort 2) |
|---|---|---|
| Cycle 1 | 25.0 ± NA | 21.4 ± NA |
| Cycle 2 (n=0, 0) | NA ± NA | NA ± NA |
Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, Vss could not be calculated.
No measurements were reported for this outcome.
| micrograms/milliliter (mcg/mL) | IMC-1121B 10 mg/kg (Cohort 3) |
|---|---|
| Cycle 1 | 493 ± 122 |
| Cycle 2 (n=2) | 793 ± 367 |
Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, Cmax could not be calculated.
No measurements were reported for this outcome.
AUC for Cycle 1 is AUC from time zero to infinity \[AUC(0-∞)\] and for Cycle 2 is AUC over a dosing interval (AUCτ).
| micrograms*hour/milliliter (mcg*h/mL) | IMC-1121B 10 mg/kg (Cohort 3) |
|---|---|
| Cycle 1 - AUC(0-∞) | 61600 ± 17100 |
| Cycle 2 - AUCτ | 103000 ± 26200 |
Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, AUC could not be calculated.
No measurements were reported for this outcome.
| hours | IMC-1121B 10 mg/kg (Cohort 3) |
|---|---|
| Cycle 1 | 234 ± NA |
| Cycle 2 (n=1) | 329 ± NA |
Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, t1/2 could not be calculated.
No measurements were reported for this outcome.
| milliliters/kilogram (mL/kg) | IMC-1121B 10 mg/kg (Cohort 3) |
|---|---|
| Cycle 1 | 40.7 ± 1.22 |
| Cycle 2 (n=0) | NA ± NA |
Due to the sparse pharmacokinetic sampling employed in Cycles 3 to 5, Vss could not be calculated.
No measurements were reported for this outcome.
Data presented are the number of participants with treatment emergent antibody positive.
| participants | IMC-1121B 6 mg/kg (Cohort 1) | IMC-1121B 8 mg/kg (Cohort 2) | IMC-1121B 10 mg/kg (Cohort 3) |
|---|---|---|---|
| Screen for the Development of Circulating Antibodies Against IMC-1121B (Immunogenicity) | 0 | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IMC-1121B 6 mg/kg (Cohort 1) | — | 1/3 (33.3%) | 3/3 (100%) |
| IMC-1121B 8 mg/kg (Cohort 2) | — | 2/6 (33.3%) | 6/6 (100%) |
| IMC-1121B 10 mg/kg (Cohort 3) | — | 2/6 (33.3%) | 6/6 (100%) |
| Event | IMC-1121B 6 mg/kg (Cohort 1) | IMC-1121B 8 mg/kg (Cohort 2) | IMC-1121B 10 mg/kg (Cohort 3) |
|---|---|---|---|
| HospitalisationSurgical and medical procedures | 1/3 | 2/6 | 1/6 |
| SyncopeNervous system disorders | 0/3 | 0/6 | 1/6 |
| Event | IMC-1121B 6 mg/kg (Cohort 1) | IMC-1121B 8 mg/kg (Cohort 2) | IMC-1121B 10 mg/kg (Cohort 3) |
|---|---|---|---|
| Vaginal haemorrhageReproductive system and breast disorders | 1/1 | 0/5 | 0/3 |
| HeadacheNervous system disorders | 1/3 | 4/6 | 5/6 |
| PyrexiaGeneral disorders | 1/3 | 2/6 | 4/6 |
| Abdominal pain upperGastrointestinal disorders | 2/3 | 0/6 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 2/3 | 2/6 | 1/6 |
| Aspartate aminotransferase increasedInvestigations | 2/3 | 2/6 | 2/6 |
| DizzinessNervous system disorders | 2/3 | 1/6 | 0/6 |
| AcneSkin and subcutaneous tissue disorders | 2/3 | 1/6 | 1/6 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 2/3 | 1/6 | 0/6 |
| FatigueGeneral disorders | 1/3 | 1/6 | 3/6 |
All participants who received at least 1 dose of study drug.
| Age, Categorical(Participants) | IMC-1121B 6 mg/kg (Cohort 1) | IMC-1121B 8 mg/kg (Cohort 2) | IMC-1121B 10 mg/kg (Cohort 3) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 6 | 4 | 13 |
| >=65 years | 0 | 0 | 2 | 2 |
| Sex: Female, Male(Participants) | IMC-1121B 6 mg/kg (Cohort 1) | IMC-1121B 8 mg/kg (Cohort 2) | IMC-1121B 10 mg/kg (Cohort 3) | Total |
|---|---|---|---|---|
| Female | 1 | 5 | 3 | 9 |
| Male | 2 | 1 | 3 | 6 |
| Race/Ethnicity, Customized(participants) | IMC-1121B 6 mg/kg (Cohort 1) | IMC-1121B 8 mg/kg (Cohort 2) | IMC-1121B 10 mg/kg (Cohort 3) | Total |
|---|---|---|---|---|
| Asian | 3 | 6 | 6 | 15 |
| Region of Enrollment(participants) | IMC-1121B 6 mg/kg (Cohort 1) | IMC-1121B 8 mg/kg (Cohort 2) | IMC-1121B 10 mg/kg (Cohort 3) | Total |
|---|---|---|---|---|
| Japan | 3 | 6 | 6 | 15 |
The record gives a start of Sep 2009, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramucirumab